Ferrous Fumarate
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
- Ferrous Fumarate
- Ferrous Fumarate: From Iron Deficiency (Indication Data Not on File) to Non-syndromic Esophageal Malformation
Ferrous Fumarate: From Iron Deficiency (Indication Data Not on File) to Non-syndromic Esophageal Malformation
One-Sentence Summary
Ferrous fumarate is an iron salt commonly used for iron supplementation, though this evidence pack does not contain formally recorded original indication or mechanism-of-action data for the drug. The TxGNN model predicts a possible association with non-syndromic esophageal malformation, but this prediction is currently supported by zero clinical trials and zero publications, and the accompanying mechanistic analysis explicitly finds no plausible biological link between iron supplementation and a congenital structural anomaly.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no licensed indication text on file (drug is not marketed in New Zealand) |
| Predicted New Indication | Non-syndromic esophageal malformation |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L5 |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for ferrous fumarate in this evidence pack. No original indication record was returned either, so a direct pharmacological comparison between the original and predicted indications cannot be constructed from the available data.
More importantly, the model's own repurposing rationale flags this specific prediction as biologically implausible: non-syndromic esophageal malformation is a congenital anatomical defect arising from failure of embryonic tracheo-esophageal septation, and it is managed surgically rather than pharmacologically. Iron salts act on iron-ion supplementation and hematopoietic support — a mechanism with no known connection to structural embryogenesis. There is therefore no credible mechanistic bridge between the drug's presumed pharmacology and this predicted indication.
Given the combination of missing drug-level data (MOA, original indication, safety label) and an explicit lack of mechanistic plausibility noted in the source rationale, this candidate should be treated as a pure model-output signal rather than a scientifically grounded repurposing hypothesis at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Ferrous fumarate is not currently marketed in New Zealand under this evidence pack, and no product authorizations are on file.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by a raw TxGNN model score (L5), with no clinical trials, no literature, and no plausible mechanistic rationale — the source analysis itself concludes there is no credible biological link between iron supplementation and a congenital esophageal structural defect. Core drug-level data (MOA, original indication, TFDA/NZ label warnings and contraindications) are also missing, which blocks even a preliminary safety assessment (S1 stage).
To proceed, the following is needed:
- Original indication and confirmed drug label data (currently missing — Blocking gap DG001)
- Mechanism of action data from DrugBank or equivalent source (High-priority gap DG002)
- An independent clinical/biological plausibility review of the non-syndromic esophageal malformation prediction before any further evidence search is warranted
- Any preclinical, case-report, or mechanistic literature that could establish a rationale, should one emerge
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.